(Q40140907)

17 September 2017

High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial (English)

1 reference

17 September 2017

phase I clinical trial

0 references

placebo

0 references

author name string

David Liebowitz

1

1 reference

17 September 2017

Jonathan D Lindbloom

2

1 reference

17 September 2017

Jennifer R Brandl

3

1 reference

17 September 2017

Shaily J Garg

4

1 reference

17 September 2017

Sean N Tucker

5

1 reference

17 September 2017

1 September 2015

1 reference

Lancet Infectious Diseases

17 September 2017

1 reference

17 September 2017

15

1 reference

17 September 2017

9

1 reference

17 September 2017

1041-1048

1 reference

Oral administration of an adenovirus vector encoding both an avian influenza A hemagglutinin and a TLR3 ligand induces antigen specific granzyme B and IFN-γ T cell responses in humans

17 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

An adenovirus-based vaccine with a double-stranded RNA adjuvant protects mice and ferrets against H5N1 avian influenza in oral delivery models

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

Response to a monovalent 2009 influenza A (H1N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

Immunological assessment of influenza vaccines and immune correlates of protection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

Decreased serologic response in vaccinated military recruits during 2011 correspond to genetic drift in concurrent circulating pandemic A/H1N1 viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

Durability of antibody responses after receipt of the monovalent 2009 pandemic influenza A (H1N1) vaccine among HIV-infected and HIV-uninfected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2815%2900266-2

7 January 2021

10.1016/S1473-3099(15)00266-2

Identifiers

DOI

1 reference

17 September 2017

1 reference